177736-05-9

Basic information

• Product Name: 4-[2-(t-butoxycarbonylamino)ethyl]benzamide
• Synonyms: 4-[2-(t-butoxycarbonylamino)ethyl]benzamide
• CAS NO: 177736-05-9
• Molecular Weight: 264.324
• Mol File: 177736-05-9.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 4-[2-(t-butoxycarbonylamino)ethyl]benzamide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[2-(t-butoxycarbonylamino)ethyl]benzamide(177736-05-9)
• EPA Substance Registry System: 4-[2-(t-butoxycarbonylamino)ethyl]benzamide(177736-05-9)

Safety Data

• Hazardous Substances Data: 177736-05-9(Hazardous Substances Data)

Upstream product

• 177736-04-8 methyl 4-[2-(tert-butoxycarbonylamino)ethyl]benzoate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 56161-89-8 4-(2-aminoethyl)-benzoic acid methyl ester-hydrochloride 

Downstream Products

• 172348-86-6 tert-butyl N-[2-(4-cyanophenyl)ethyl]carbamate 
• 90513-12-5 4‐(2‐aminoethyl)benzamide 

Relevant articles and documents

Design and Synthesis of New 1,3,5-Trisubstituted Triazines for the Treatment of Cancer and Inflammation

Low-molecular-weight synthetic molecules 1 with the general 2-(fluorophenylamino)-4,6-disubstituted 1,3,5-triazine structure and showing anti-inflammatory and anticancer activities were explored. Structure–activity relationship studies demonstrated the importance of the aminopentyl chain, the 3- or 4-fluorophenylaniline component, and the presence of at least one substituent, such as a tyramine moiety, attached directly to the triazine ring as essential for good activity. These compounds, represented by leads 4-{2-[4-(5-Aminopentylamino)-6-(3-fluorophenylamino)-1,3,5-triazin-2-ylamino]ethyl}phenol (6) and 4-{2-[4-(5-Aminopentylamino)-6-(4-fluorophenylamino)-1,3,5-triazin-2-ylamino]ethyl}phenol (10), displayed moderate and significant in vitro and in vivo dual activities, respectively, and address the molecular link between inflammation and cancer. Compound 10 demonstrated significant antitumor efficacy upon administration by the oral and intravenous routes in several animal models. This class of triazine compounds is new, safe, and nontoxic and offers a novel approach to the treatment of inflammation and cancer.

NAPHTHALENE AMIDES HAVING LEUKOTRIENE-ANTAGONISTIC ACTION

Naphthalene amides of formula (I) wherein the substituent containing A is bound to the 6- or 7- position of the 2-naphthol system; the substituent containing B is bound to the benzene ring at any free position; R is hydrogen or methyl; R is hydrogen, fluorine, chlorine or -OCH3, which is bound to the naphthalene system at any positions except the 2- and the one occupied by the other substituent; R is hydrogen, fluorine, chlorine or bromine; A- is -CO-NR- or -NR-CO- group, wherein R is hydrogen or methyl; B is a 5-tetrazolyl or -COOR group, wherein R is hydrogen, a (C1-C4)-alkyl or a phenylalkyl group of less than 10 carbon atoms; m is 0 or 1; n and p are integers from 0 to 6, with the proviso that n + p is less or equal to 6; as well as the solvates and pharmaceutically acceptable salts thereof, have leukotriene antagonistic action.